# BioNexus Gene Lab Corp: overview BGLC · Nasdaq · CIK 1737523 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/bglc.md) · [Financials](/companies/bglc/financials.md) · [Filings](/companies/bglc/filings.md) · [Insiders](/companies/bglc/insiders.md) Latest reported revenue: [$76.2k](/filings/0001477932-26-005093.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:Revenues, accession 0001477932-26-005093). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [2,630](/filings/0001477932-25-008343.md) | [2,524 d](/filings/0001477932-26-002218.md) | [2,137](/filings/0001477932-26-003242.md) | [2,260](/filings/0001477932-26-005093.md) | [2,544](/filings/0001477932-25-008343.md) | [484 d](/filings/0001477932-26-002218.md) | [22.8](/filings/0001477932-26-003242.md) | [76.2](/filings/0001477932-26-005093.md) | | Gross margin | % | [12.4%](/filings/0001477932-25-008343.md) | [12.3% d](/filings/0001477932-26-002218.md) | [16.1%](/filings/0001477932-26-003242.md) | [16.3%](/filings/0001477932-26-005093.md) | [14.8%](/filings/0001477932-25-008343.md) | [(0.8%) d](/filings/0001477932-26-002218.md) | [(3.5%)](/filings/0001477932-26-003242.md) | [17.0%](/filings/0001477932-26-005093.md) | | Operating margin | % | [(50.9%)](/filings/0001477932-25-008343.md) | [(16.5%) d](/filings/0001477932-26-002218.md) | [(28.9%)](/filings/0001477932-26-003242.md) | [(27.0%)](/filings/0001477932-26-005093.md) | [(27.6%)](/filings/0001477932-25-008343.md) | [(213.5%) d](/filings/0001477932-26-002218.md) | [(2366.2%)](/filings/0001477932-26-003242.md) | [(370.8%)](/filings/0001477932-26-005093.md) | | Net margin | % | [(51.1%)](/filings/0001477932-25-008343.md) | [(13.8%) d](/filings/0001477932-26-002218.md) | [(29.2%)](/filings/0001477932-26-005093.md) | [(27.3%)](/filings/0001477932-26-005093.md) | [(27.9%)](/filings/0001477932-25-008343.md) | [(214.2%) d](/filings/0001477932-26-002218.md) | [(2379.7%)](/filings/0001477932-26-005093.md) | [(376.1%)](/filings/0001477932-26-005093.md) | | Diluted EPS | $ per share | [(0.75)](/filings/0001477932-25-008343.md) | not reported | [(0.35)](/filings/0001477932-26-003242.md) | [(0.34)](/filings/0001477932-26-005093.md) | [(0.40)](/filings/0001477932-25-008343.md) | not reported | [(0.23)](/filings/0001477932-26-003242.md) | [(0.12)](/filings/0001477932-26-005093.md) | | Free cash flow | $k | [(1,802) d](/filings/0001477932-25-008343.md) | [215 d](/filings/0001477932-26-002218.md) | [(833)](/filings/0001477932-26-003242.md) | [(759) d](/filings/0001477932-26-005093.md) | [(1,243) d](/filings/0001477932-25-008343.md) | [960 d](/filings/0001477932-26-002218.md) | [(148)](/filings/0001477932-26-003242.md) | [(423) d](/filings/0001477932-26-005093.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [13.4](/filings/0001477932-23-002002.md) | [10.9](/filings/0001477932-24-002151.md) | [9.8](/filings/0001477932-25-002725.md) | [9.5](/filings/0001477932-26-002218.md) | [7.4](/filings/0001477932-26-002218.md) | | Gross margin | % | [17.0%](/filings/0001477932-23-002002.md) | [11.5%](/filings/0001477932-24-002151.md) | [13.6%](/filings/0001477932-25-002725.md) | [13.6%](/filings/0001477932-26-002218.md) | [14.6%](/filings/0001477932-26-002218.md) | | Operating margin | % | [7.9%](/filings/0001477932-23-002002.md) | [(2.7%)](/filings/0001477932-24-002151.md) | [(26.5%)](/filings/0001477932-25-002725.md) | [(16.5%)](/filings/0001477932-26-002218.md) | [(39.9%)](/filings/0001477932-26-002218.md) | | Net margin | % | [5.6%](/filings/0001477932-23-002002.md) | [(3.3%)](/filings/0001477932-24-002151.md) | [(26.9%)](/filings/0001477932-25-002725.md) | [(16.8%)](/filings/0001477932-26-002218.md) | [(40.2%)](/filings/0001477932-26-002218.md) | | Diluted EPS | $ per share | not reported | not reported | [(0.17)](/filings/0001477932-25-002725.md) | [(0.09)](/filings/0001477932-25-002725.md) | not reported | | Free cash flow | $m | [0.0](/filings/0001477932-23-002002.md) | [0.6](/filings/0001477932-24-002151.md) | [(2.0)](/filings/0001477932-25-002725.md) | [(2.3)](/filings/0001477932-26-002218.md) | [(1.9)](/filings/0001477932-26-002218.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bglc/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $197 | 101 | | Reduced −130 | | [HRT FINANCIAL LP](/funds/1475597.md) | 2026-06-30 | $27 | 14,283 | | New +14,283 | | [Caitong International Asset Management Co., Ltd](/funds/1963355.md) | 2026-06-30 | $2 | 1 | | New +1 | ## Recent filings [All 157 filings](/companies/bglc/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-07 | 13:00 ET | [8-K](/filings/0001477932-26-006075.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001477932-26-006075 | | 2026-08-14 | 21:29 ET | [SCHEDULE 13D](/filings/0001520138-26-000354.md) | Ownership report, active investor | 0001520138-26-000354 | | 2026-08-14 | 21:00 ET | [10-Q](/filings/0001477932-26-005093.md) | Quarterly report, period 2026-06-30 | 0001477932-26-005093 | | 2026-07-28 | 18:30 ET | [8-K](/filings/0001477932-26-004556.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001477932-26-004556 | | 2026-06-05 | 13:00 ET | [8-K](/filings/0001477932-26-003658.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001477932-26-003658 | | 2026-05-15 | 21:15 ET | [10-Q](/filings/0001477932-26-003242.md) | Quarterly report, period 2026-03-31 | 0001477932-26-003242 | | 2026-04-14 | 21:20 ET | [10-K](/filings/0001477932-26-002218.md) | Annual report, period 2025-12-31 | 0001477932-26-002218 | | 2026-03-17 | 18:30 ET | [8-K](/filings/0001477932-26-001379.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001477932-26-001379 | | 2026-02-23 | 13:35 ET | [8-K](/filings/0001477932-26-000964.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001477932-26-000964 | | 2026-02-03 | 21:10 ET | [8-K](/filings/0001477932-26-000610.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001477932-26-000610 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001477932-26-002218.md), filed Apr 14, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/c993fe21-97b5-49a0-8bfe-2f211589397b) ## About the filer - CIK: 1737523 - Tickers: BGLC - Exchange: Nasdaq - SIC code: 8071 Services-Medical Laboratories - State of incorporation: WY - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.